SightGlass Vision, Inc. Presents their Two Year Data for Myopia Control Efficacy for Vision Spectacle Lenses

Glasses which use SightGlass Vision Diffusion Optics Technology have demonstrated success in slowing the progression of myopia in children. This is based on a 24-month interim data from the clinical trial ARVO 2022.

There was an analysis undertaken of full-time glasses wearers, between the ages of 6 and 10, whose parents reported a lack of near vision improvement with the use of study spectacles. With the Diffusion Optics Technology lenses, there were statistically significant improvements between the groups.

The study was conducted by enrolling, randomising, and dispensing the lenses to 256 eligible children over 14 clinical trials, which were held in the United States and Canada.

Lenses which use the patent protected SightGlass Vision Diffusion Optics Technology include ‘thousands of micro-dots that softly scatter light to reduce contrast on the retina.’ This method aims to reduce the progression of myopia in children.

“We’re enthusiastic about sharing more detail from the two-year interim results, which will further support our development efforts and ongoing commercialization activities in select markets.” Andrew Sedgwick, CEO of SightGlass Vision.

Myopia is the leading cause of visual impairment in children. SightGlass Vision's data is a promising and exciting development in treating it.

To stay up to date with the latest eye care news and vacancies follow Vision Executives!